The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

T he U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

About Dupixent Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites. ... DUPIXENT can cause allergic reactions that can sometimes be severe.

Dupixent is intended for injection under the skin (subcutaneous injection) and is given every other week. It can be given in a clinic or at home by self-administration after training by a ...

Dupixent comes as a liquid solution inside prefilled, single-use injection pens or syringes. It’s given as an injection under your skin . Dupixent’s active ingredient is dupilumab, a biologic .

TORONTO, Sept. 12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The most common adverse reaction reported with dupilumab in all 3 CUPID trials were injection site reactions. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or ...

Dupixent is given as a subcutaneous injection. In adults, the recommended dosage of Dupixent is 300 mg given once per week. In children, the recommended dosage of Dupixent depends on their weight.